From the FDA Drug Label
8.4 Pediatric Use Safety and effectiveness in pediatric patients have not been established.
The FDA drug label does not support the administration of meclizine to pediatric patients, as safety and effectiveness have not been established in this population 1.
From the Research
Meclizine can be used in pediatric patients, but it's generally recommended for children 12 years and older, with careful consideration of dosage and potential side effects, as evidenced by the most recent study in 2020 2. When considering meclizine for pediatric use, it's essential to start with the lowest effective dose to minimize side effects such as drowsiness, dry mouth, and blurred vision. The medication works by blocking histamine H1 receptors and affecting the vestibular system to reduce sensitivity to motion.
Key Considerations
- Meclizine is not FDA-approved for children under 12 years, though some physicians may prescribe it off-label for younger children with careful dosage adjustments based on weight.
- For children under 12 who need treatment for motion sickness or vertigo, consult with a pediatrician as alternative medications like dimenhydrinate (Dramamine) may be more appropriate with established pediatric dosing guidelines.
- Always monitor children closely for side effects when starting any antihistamine medication.
Dosage and Administration
- For children aged 12 and above, the typical dosage is 12.5 to 25 mg taken up to three times daily as needed for motion sickness or vertigo.
- The most recent study in 2020 2 suggests that meclizine may be effective in reducing motion sickness, but its use may be counterproductive in high-acceleration environments.
Important Notes
- Meclizine's efficacy and specific mechanism have come into question, and its use should be carefully considered in pediatric patients.
- The study in 2012 3 provides information on meclizine's pharmacokinetics, but it does not directly address its use in pediatric patients.
- Other studies, such as those in 2009 4, 1991 5, and 1999 6, provide additional information on meclizine's effects, but they are not as relevant to the question of its use in pediatric patients as the most recent study in 2020 2.